Shanghai Henlius Biotech (SEHK:2696) has entered a strategic partnership with Forlong Biotechnology to jointly develop next-generation cancer immunotherapies. This move brings together Henlius’s antibody expertise and Forlong’s engineered cytokine technologies, further expanding Henlius’s oncology pipeline.
See our latest analysis for Shanghai Henlius Biotech.
Shanghai Henlius Biotech’s latest partnership news comes at a time when its stock has seen remarkable momentum, with the 1-year total shareholder return standing at a striking 218.95%. The share price has surged nearly 200% so far this year, signaling renewed confidence and growth potential, even with some typical short-term volatility along the way.
If breakthroughs in cancer immunotherapy spark your curiosity, consider broadening your outlook and discover more standout healthcare innovators through our See the full list for free..
But with the stock’s meteoric…
